RDHL
Redhill Biopharma Ltd-sp Adr
$0.43
Earnings Summary
Revenue | $1.8Mn |
Net Profits | $0.76Mn |
Net Profit Margins | 42.37% |
PE Ratio | 0.11 |
Highlights
Redhill Biopharma Ltd-sp Adr’s revenue fell -90.21% since last year same period to $1.8Mn in the Q2 2023. On a quarterly growth basis, Redhill Biopharma Ltd-sp Adr has generated -85.97% fall in its revenue since last 3-months.
Redhill Biopharma Ltd-sp Adr’s net profit jumped 105.34% since last year same period to $0.76Mn in the Q2 2023. On a quarterly growth basis, Redhill Biopharma Ltd-sp Adr has generated -69.44% fall in its net profits since last 3-months.
Redhill Biopharma Ltd-sp Adr’s net profit margin jumped 154.5% since last year same period to 42.37% in the Q2 2023. On a quarterly growth basis, Redhill Biopharma Ltd-sp Adr has generated 117.78% jump in its net profit margins since last 3-months.
Redhill Biopharma Ltd-sp Adr’s price-to-earnings ratio after this Q2 2023 earnings stands at 0.11.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Redhill Biopharma Ltd-sp Adr post its latest quarter earnings
EPS Estimate Current Year | -0.03 |
Highlights
Redhill Biopharma Ltd-sp Adr’s earning per share (EPS) estimates for the current year stand at -0.03.
Key Ratios
Key ratios of the Redhill Biopharma Ltd-sp Adr post its Q4 2023 earnings
Earning Per Share (EPS) | -0.2 |
Highlights
Redhill Biopharma Ltd-sp Adr’s earning per share (EPS) jumped 0% since last year same period to -0.2 in the Q4 2023. This indicates that the Redhill Biopharma Ltd-sp Adr has generated 0% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-02-12 | -0.03 | -0.2 | -566.67% |
₹0 US Stocks a/c Opening Fee